Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  International Angiology

• Publication date

  2016-12-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.23736/S0392-9590.16.03785-8PMID 27982558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Duration of anticoagulation after isolated pulmonary embolism

  2016cited by this paper
• The association of statin therapy with the risk of recurrent venous thrombosis

  2016cited by this paper
• Residual pulmonary obstruction and the risk of late complications in patients with pulmonary embolism.

  2016cited by this paper
• Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism.

  2016cited by this paper
• A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES).

  2016cited by this paper
• Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer

  2015cited by this paper
• Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis

  2015cited by this paper
• Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism

  2015cited by this paper
• Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts

  2015cited by this paper
• Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data

  2015cited by this paper
• The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation

  2015cited by this paper
• New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials

  2015cited by this paper
• Residual vein thrombosis and the risk of subsequent serious complications.

  2015cited by this paper
• Sulodexide for the Prevention of Recurrent Venous Thromboembolism

  2015cited by this paper
• Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism

  2015cited by this paper
• Role of family history of venous thromboembolism and thrombophilia as predictors of recurrence: a prospective follow‐up study

  2015cited by this paper
• Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis.

  2015cited by this paper
• Duration of anticoagulation after venous thromboembolism in real world clinical practice.

  2015cited by this paper
• New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?

  2015cited by this paper
• D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

  2015cited by this paper
• Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.

  2015cited by this paper
• Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration

  2014cited by this paper
• d‐Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model

  2014cited by this paper
• Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

  2014cited by this paper
• D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study.

  2014cited by this paper
• Optimal duration of anticoagulation

  2014cited by this paper
• Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case–control study

  2014cited by this paper
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

  2014cited by this paper
• Unexpectedly high recanalization rate in patients with pulmonary embolism treated with anticoagulants alone.

  2014cited by this paper
• Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials

  2013cited by this paper
• Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

  2013cited by this paper
• Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study

  2013cited by this paper
• Oral apixaban for the treatment of acute venous thromboembolism.

  2013cited by this paper
• Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis

  2013cited by this paper
• Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

  2013cited by this paper
• Statin treatment and the risk of recurrent pulmonary embolism.

  2013cited by this paper
• Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism

  2013cited by this paper
• Apixaban for extended treatment of venous thromboembolism.

  2013cited by this paper
• Family history of venous thromboembolism (VTE) as a predictor for recurrent VTE in unprovoked VTE patients

  2013cited by this paper
• Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

  2012cited by this paper
• Aspirin for preventing the recurrence of venous thromboembolism.

  2012cited by this paper
• Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)

  2012cited by this paper
• Low-dose aspirin for preventing recurrent venous thromboembolism.

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Long-term outcome of patients with persistent vascular obstruction on computed tomography pulmonary angiography 6 months after acute pulmonary embolism

  2012cited by this paper
• Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review

  2011cited by this paper
• Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials

  2011cited by this paper
• Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model

  2010cited by this paper
• Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis

  2010cited by this paper
• Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism

  2010cited by this paper
• Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry

  2010cited by this paper
• Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study.

  2010cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Statin use and the prevention of venous thromboembolism: a meta‐analysis

  2010cited by this paper
• Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A

  2010cited by this paper
• Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism

  2010cited by this paper
• Elevated d‐dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta‐analysis

  2009cited by this paper
• Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.

  2009cited by this paper
• Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.

  2009cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• Overweight, obesity, and the risk of recurrent venous thromboembolism.

  2008cited by this paper
• Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy

  2008cited by this paper
• Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.

  2008cited by this paper
• Systematic Review: d-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism

  2008cited by this paper
• Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study.

  2008cited by this paper
• Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study.

  2008cited by this paper
• The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

  2007cited by this paper
• Ventilation–Perfusion Scintigraphy Is More Sensitive than Multidetector CTPA in Detecting Chronic Thromboembolic Pulmonary Disease as a Treatable Cause of Pulmonary Hypertension

  2007cited by this paper
• Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review.

  2006cited by this paper
• D-dimer testing to determine the duration of anticoagulation therapy.

  2006cited by this paper
• The post‐thrombotic syndrome: risk factors and impact on the course of thrombotic disease

  2005cited by this paper
• Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor

  2004cited by this paper
• Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia

  2003cited by this paper
• D-dimer levels and risk of recurrent venous thromboembolism.

  2003cited by this paper
• Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

  2003cited by this paper
• Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

  2003cited by this paper
• Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped

  2002cited by this paper
• Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis.

  2002cited by this paper
• Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism

  2002cited by this paper

• Surgical management of cerebral venous sinus thrombosis: Case series and literature review

  2021cites this paper
• Risk Of Recurrence After Withdrawal Of Anticoagulation In Patients With Unprovoked Venous Thromboembolism: External Validation Of The Vienna Nomogram And The Dash Prediction Score.

  2019cites this paper
• Risk of Recurrence After Withdrawal of Anticoagulation in Patients With Unprovoked Venous Thromboembolism: External Validation of the Vienna Nomogram and the Dash Prediction Score

  2019cites this paper